(Q37921278)

25 August 2017

1 reference

title

Management of recurrent head and neck cancer: recent progress and future directions (English)

1 reference

25 August 2017

1 reference

1 reference

head and neck carcinoma

1 reference

Bruce E Brockstein

1

1 reference

25 August 2017

language of work or name

1 reference

1 August 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

71

1 reference

25 August 2017

issue

12

1 reference

25 August 2017

page(s)

1551-1559

1 reference

https://scigraph.springernature.com/pub.10.2165/11592540-000000000-00000

25 August 2017

exact match

0 references

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

21 January 2018

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Salvage re-irradiation for recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Phase II study of sunitinib malate in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592540-000000000-00000

A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers

21 January 2018

1 reference

12 December 2020

A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer

1 reference

12 December 2020

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

1 reference

12 December 2020

Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial.

1 reference

12 December 2020

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas

1 reference

12 December 2020

Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate

1 reference

12 December 2020

Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPV-unrelated sites in a multicultural population: the British Columbia experience

1 reference

12 December 2020

A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group

1 reference

12 December 2020

Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.

1 reference

12 December 2020

A randomized trial of the combination of cis-platinum, oncovin and bleomycin (COB) versus methotrexate in patients with advanced squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study

1 reference

12 December 2020

Prognostic factors for survival after salvage reirradiation of head and neck cancer

1 reference

12 December 2020

10.2165/11592540-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1013602786

0 references

Fatcat ID

release_zjx5wgsny5ayxeb35ofjck65nm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zjx5wgsny5ayxeb35ofjck65nm

24 November 2022

mapped directly with Wikidata item

1 reference